Cannabis companies preparing for a U.S. IPO under SEC registration require a PCAOB-registered auditor to perform audits of their financial statements. Three fiscal years of audited financial statements are typically required for a full S-1 registration (or two years for smaller reporting companies). PCAOB standards involve stricter independence, quality control, and documentation requirements than a standard GAAS audit. GreenGrowth CPAs is PCAOB registered and experienced with cannabis-specific 280E disclosure requirements, SEC registration, and the unique compliance challenges of cannabis operators pursuing U.S. public listings.

A reverse merger is an alternative path to going public where a private company merges with an existing public shell company, becoming publicly listed without going through the full traditional IPO underwriting process. Reverse mergers can be faster and less expensive than a traditional IPO, but still require PCAOB-audited financial statements, SEC compliance, and financial disclosure. Cannabis operators sometimes use reverse mergers into OTC-listed shells as a first step, followed by an uplisting to NYSE or NASDAQ once the operator meets national exchange listing standards. GreenGrowth CPAs supports cannabis operators through both traditional IPO and reverse merger paths.

A SPAC (Special Purpose Acquisition Company) is a shell company that raises capital through an IPO with the specific purpose of acquiring an existing private company, effectively taking the target public through the merger. Cannabis-focused SPACs became more common post-Schedule III as U.S. capital markets access expanded for cannabis operators. SPAC transactions require PCAOB-audited financial statements from the target, quality of earnings analysis, and coordinated accounting for the de-SPAC merger. GreenGrowth CPAs supports cannabis operators on the target side of SPAC transactions with financial preparation, audit, and combined entity accounting.

Sarbanes-Oxley (SOX) requires public companies to maintain and document internal controls over financial reporting. Implementing SOX controls before going public, rather than after, significantly reduces the risk of material weaknesses and deficiencies being identified and publicly disclosed post-listing. Cannabis operators face additional SOX complexity around cash handling, banking access limitations, and 280E documentation. GreenGrowth CPAs helps cannabis companies build SOX-ready control frameworks as part of the pre-IPO process.

Ideally 12 to 24 months before a planned listing. Early engagement allows time for financial statement conversion to PCAOB-audited standards for the three historical fiscal years required by S-1, SOX readiness implementation, SEC registration support, 280E disclosure preparation, and coordination with underwriters and legal counsel. Cannabis operators that engage too late often face delays, restated audits, and additional costs during the process. For operators expecting to file within 12 months, we can accelerate the workstream with a compressed timeline.

An S-1 is the SEC registration statement used by U.S.-based companies going public on a U.S. exchange. An F-1 is the equivalent registration statement used by foreign private issuers listing in the U.S. Both require audited financial statements (typically three years, or two for smaller reporting companies), MD&A, risk factors, and detailed financial disclosures. Cannabis operators headquartered outside the U.S. pursuing a U.S. listing would typically file an F-1. The choice depends on the issuer's jurisdiction and reporting obligations.

OTC markets have lower listing standards and are often the first public trading venue for cannabis operators. OTC listings can be achieved via direct SEC registration or reverse merger into an existing OTC shell. NYSE and NASDAQ have significantly higher listing thresholds including minimum market cap, minimum share price, minimum public float, corporate governance standards, and stricter reporting obligations. Many cannabis operators start on OTC then uplist to NYSE or NASDAQ once they meet the requirements. GreenGrowth CPAs supports both initial OTC listings and OTC-to-national-exchange uplistings.

The April 22, 2026 federal rescheduling of state-licensed medical cannabis to Schedule III materially changed the U.S. capital markets landscape for cannabis operators. Medical cannabis operations became eligible to deduct ordinary business expenses at the federal level (removing 280E for medical revenue), improving financial performance and IPO valuations. U.S. institutional investors that were previously blocked from cannabis exposure have expanded their appetite for medical-focused operators. Cannabis IPO activity on NYSE, NASDAQ, and OTC has increased materially since April 2026, particularly among operators with medical-focused revenue mixes and vertically integrated MSOs.